<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="361972">
  <stage>Registered</stage>
  <submitdate>25/01/2012</submitdate>
  <approvaldate>30/01/2012</approvaldate>
  <actrnumber>ACTRN12612000131853</actrnumber>
  <trial_identification>
    <studytitle>Is amitriptyline effective in the management of chronic low back pain?</studytitle>
    <scientifictitle>Is low dose amitriptyline more effective than an active placebo in the management of chronic low back pain? A double-blind, randomized, placebo-controlled trial.</scientifictitle>
    <utrn>U1111-1127-3216</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic low back pain</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Low-dose amitriptyline; 25mg per day; capsule/oral administration; 6 month duration</interventions>
    <comparator>Benztropine mesylate; 1mg per day; capsule/oral administration; 6 month duration</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain intensity
Measured on the Descriptor Differential Scale (DDS)
Mean pain score
Decrease of 2 units on the DDS</outcome>
      <timepoint>Baseline and 3 and 6 months after intervention commenced</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pain intensity measured on the visual analog scale (VAS, 0-100)
Mean pain score
Minimally clinically important difference: Improvement of 15 points on the VAS
</outcome>
      <timepoint>Baseline and 3 and 6 months after intervention commenced.
</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Functional status measured on the Roland Morris Disability Questionnaire (RMDQ); 
Mean Disability Score;
Minimally clinically important difference: Improvement of 13-16% in disability or 3-4 points on RMDQ.</outcome>
      <timepoint>Baseline and 3 and 6 months after intervention commenced</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Paid/unpaid work absence and hindrance/productivity measured on Short Form Health and Labour Questionnaire (SFHLQ) </outcome>
      <timepoint>Baseline and each month for 6 months after intervention commenced</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Aged 18-75 years
2. Chronic low back pain (Chronic &gt; 3 months in duration; pain in the region bordered above by the costal margin and below by the gluteal folds)
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Specific pathological entities, such as infection, metastasis, osteoporosis, fractures. 
- Major co-existing illness which might confound assessment of function or for which amitriptyline may be inappropriate
- Another significant musculoskeletal conditions
- History of psychosis
- Patients with any diagnosed depression with or without the use of medication
- Any prior or current use of antidepressants
- Current use of opioids
- Any contra-indication or allergy to amitriptyline
- Pregnancy or planning/trying to become pregnant or breastfeeding
- Inability to provide informed consent
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment will be ensured by the use of identical, active placebo, and the use of a central 
automated allocation procedure, with security in place to ensure allocation data cannot be accessed 
or influenced by any person.</concealment>
    <sequence>Randomisation will be based on computer generated random numbers prepared by a statistician who had no involvement in conducting the trial. </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>10/02/2012</anticipatedstartdate>
    <actualstartdate>30/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/11/2015</actualenddate>
    <samplesize>150</samplesize>
    <actualsamplesize>146</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <postcode>3181</postcode>
    <postcode>3004</postcode>
    <postcode>3065</postcode>
    <postcode>3079</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Monash University</primarysponsorname>
    <primarysponsoraddress>Department of Epidemiology and Preventive Medicine 
School of Public Health and Preventive Medicine
Monash University
Alfred Hospital
Commercial Road
Melbourne Vic  3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Alfred Research Ethics Committee</sponsorname>
      <sponsoraddress>Alfred Research Ethics Committee
Alfred Hospital
Commercial Road
Prahran 3181
Vic</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>VU University</othercollaboratorname>
      <othercollaboratoraddress>VU University
De Boelelaan 1085, room U454
1081 HV Amsterdam</othercollaboratoraddress>
      <othercollaboratorcountry>Netherlands</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Ageing Research Institute</othercollaboratorname>
      <othercollaboratoraddress>34/54 Poplar Rd  
Parkville 
VIC 3052</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Chronic low back pain is a major public health problem. Antidepressants are one commonly prescribed treatment for low back pain, and are used not only to treat depression and insomnia, but chronic pain. Their use is rapidly increasing, despite lack of supportive evidence and conflicting recommendations from clinical guidelines.

Aims: In community-based adults with chronic low back pain, we aim to determine:
1. If low dose amitriptyline (tricyclic antidepressant) is more effective than an active placebo in the management of pain
2. If low dose amitriptyline is more effective than an active placebo in improving disability and reducing work absence and hindrance.

Methods: A double-blind, randomized, placebo-controlled trial will be conducted. We will recruit 150 subjects with chronic low back pain. Participants will receive low-dose amitriptyline or an active placebo for 6 months. Pain, disability and work absence and hindrance will be assessed at baseline, 3 and 6 months using valid measures. 

Implications: If antidepressants are found to be effective, it will provide high quality evidence for their use, potentially enabling this treatment option to be considered by more individuals with chronic low back pain. If we do not find antidepressants to be effective, then this trial will provide strong evidence to review international guidelines that recommend their use and to evaluate the extensive use of tricyclic antidepressants for chronic low back pain.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Research Ethics Committee</ethicname>
      <ethicaddress>55 Commercial Rd, 
Melbourne VIC 3004</ethicaddress>
      <ethicapprovaldate>23/12/2011</ethicapprovaldate>
      <hrec>HREC/12/Alfred/16, 476/11</hrec>
      <ethicsubmitdate>25/11/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Eastern Health Human Research Ethics Committee</ethicname>
      <ethicaddress>The Office of Research and Ethics
Level 2
5 Arnold Street
Box Hill VIC 3128</ethicaddress>
      <ethicapprovaldate>5/09/2012</ethicapprovaldate>
      <hrec>SERP28/1112</hrec>
      <ethicsubmitdate>15/05/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash University Human Research Ethics Committee</ethicname>
      <ethicaddress>Monash University
Level 1, Chancellery Building D, Clayton Campus
26 Sports Walk
Clayton VIC 3800
Australia</ethicaddress>
      <ethicapprovaldate>1/02/2012</ethicapprovaldate>
      <hrec>CF12/0271 - 2012000106</hrec>
      <ethicsubmitdate>13/01/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Dr Donna Urquhart or Prof Flavia Cicuttini</name>
      <address>Department of Epidemiology and Preventive Medicine 
School of Public Health and Preventive Medicine
Monash University
Alfred Hospital
Commercial Road
Melbourne Vic  3004
Australia</address>
      <phone>+61 3 9903 0555</phone>
      <fax>+61 3 9903 0556</fax>
      <email>Donna.Urquhart@monash.edu OR Flavia.Cicuttini@monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Ms Judy Hankin / Ms Alice Noone</name>
      <address>Department of Epidemiology and Preventive Medicine 
School of Public Health and Preventive Medicine
Monash University
Alfred Hospital
Commercial Road
Melbourne Vic  3004
Australia</address>
      <phone>+61 3 9903 0553</phone>
      <fax>+61 3 9903 0556</fax>
      <email>Judy.Hankin@monash.edu OR Alice.Noone@monash.edu</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Donna Urquhart</name>
      <address>Department of Epidemiology and Preventive Medicine 
School of Public Health and Preventive Medicine
Monash University
Alfred Hospital
Commercial Road
Melbourne Vic  3004
Australia</address>
      <phone>+61 3 9903 0555</phone>
      <fax>+61 3 9903 0556</fax>
      <email>Donna.Urquhart@monash.edu</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Donna Urquhart</name>
      <address>Monash University
The Alfred Centre
99 Commercial Road
Melbourne VIC 3004</address>
      <phone>61 3 9903 0555</phone>
      <fax />
      <email>Donna.urquhart@monash.edu</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>